More than a year since the onset of the SARS-COV-2 viral pandemic, the situation continues to be serious, with the latest data recording more than 160 million confirmed cases and almost 3.4 million deaths worldwide. New waves of infection have emerged even in countries that looked to have brought their conditions under control, and in many countries, the outbreak continues unabated. Reining in the pandemic and bringing it to an end will require multifaceted, multistakeholder approaches including public health risk-mitigation measures, community education and empowerment strategies, and successful development and deployment of vaccination programs worldwide.

Through a combination of global cooperation and innovation, the scientific community has managed to develop multiple vaccine candidates against SARS-COV-2. Some of these have successfully completed phase III trials, received emergency authorization, and are already being used in multiple nations to reduce the spread of the pandemic. Unfortunately, the development of safe and effective vaccines is only part of a comprehensive vaccination solution. Challenges in vaccinating a country’s entire population include the speed in which the vaccines can be manufactured and transported to wherever they are needed; the successful organization and management of vaccine delivery programs on the ground; and how well vaccines are accepted by potential recipients.

People living with cancer (PLWC) have been severely affected during this pandemic. Not only are PLWCs at higher risk of contracting COVID-19 infections, but they are also more susceptible to complications when infected with the disease. Additionally, the pandemic has also caused a detrimental impact on cancer care services for PLWCs, with delays and disruptions tied to poorer outcomes. For example, recent data projected that because of the pandemic, clinicians in Europe saw 1.5 million fewer patients with cancer over the past year, with an estimated one in five PLWCs in Europe not receiving the care they needed.

Cancer civil society organizations (CCSOs) have also been faced with numerous challenges connected to the pandemic, which have affected their ability to support PLWCs. Many of them have adapted innovative solutions and new approaches to continue providing much-needed services, while quite a few have also taken on completely new roles to cater to the evolving needs of the PLWC communities they serve in the pandemic.

As vaccination programs begin to be rolled out across different low- and middle-income countries (LMICs), questions arise on whether CCSOs should take on new roles to support COVID-19 vaccination programs. This is especially relevant since successful rollout of vaccination has been suggested to be one of the ways to get cancer care back on track. This commentary explores issues around potential roles CCSOs should play in COVID-19 vaccination programs in LMICs.

Why Can CCSOs Play a Role in Covid-19 Vaccination Programs?

There are some significant challenges in advancing vaccination efforts globally. Chief among these is vaccine hesitancy. The multifaceted determinants of vaccine hesitancy (as depicted in Figure 1) can be divided into (1) confidence in the efficacy and safety of the vaccines as well as the system tasked with the process of vaccination; (2) complacency—in which individuals are not motivated to be vaccinated if the perceived risk of the specific disease is low; and (3) convenience—in which the ease (or difficulty) of obtaining the vaccine affects the decision to get vaccinated.

Numerous studies have documented the continuing lack of confidence in the safety and efficacy of COVID-19 vaccines among the public, including PLWCs.
This has been attributed mainly to a paucity of context-specific communications to relevant communities and active disinformation campaigns from antivaccine and pseudoscience groups. CCSOs, as trusted institutions among PLWCs, can use their trusted reputation and social capital to aid in confidence-building and acceptance in vaccines among the communities they work in. One way they could support PLWCs is to help them understand their relative risk. For example, in the United States, a part of the initial fear of taking the Pfizer-BioNTech vaccine a few weeks after its approval and use was attributed to reported cases of Bell’s palsy. CCSOs can play an active role in helping PLWCs to simplify and distil the plethora of news and studies, which can be one of the ways to boost confidence in vaccines.

PLWCs as well as health care workers working in cancer care may also be complacent toward COVID-19 vaccinations, with the unfounded perception by some of being at lower risk to contract the disease, while others may feel that vaccination is futile because of the complex emotional stresses and mental health issues they face currently. CCSOs, especially those working within the psychosocial landscape, can assist in identifying individuals with vaccine complacency as well as those with mental health issues, which may be affecting vaccine acceptance, and carry out individual or group-level interventions as and when required for this purpose.

Vaccination programs will most likely need to be carried out via multiple modalities, with modifications to take into account varying geographical locations, local context, and even specific cultural mindsets. PLWCs are diverse and heterogeneous, with individuals living with different cancers as well as being in different stages of survivorships on different treatment regimens. Additionally, the clinical trials that led to the approval of a number of the vaccines did not include enough patients with cancer on active treatment to generate ample evidence for patients with cancer vis-à-vis the state of their immune cells. This has led to diverse recommendations and, in some instances, confusion among patients with cancer on active treatment to generate ample evidence for patients with cancer vis-à-vis the state of their immune cells. This has led to diverse recommendations and, in some instances, confusion among patients with cancer on whether or not to vaccinate against COVID-19. Large-scale mass vaccination programs may find it challenging to assess and manage these individual needs of PLWCs. CCSOs, by contrast, may be better suited to bridge this gap between health authorities, oncologists, and the patients themselves to facilitate vaccinations among PLWCs.

PLWCs have been indicated as an at-risk group who need to be prioritized for vaccinations. In the tussle between vaccine supply and the race for vaccination even within each country, concerns abound on equitable distribution of vaccines. CCSOs are institutional advocates for PLWCs and can raise concerns to key stakeholders as well as play an oversight role over distributions to ensure PLWCs are indeed prioritized and provided with access to vaccines in a timely manner. CCSOs are well positioned to be able to address ethnic, sex, economic, geographic, and cultural diversities of the communities they work with and can use their institutional knowledge and social capital to triage and prioritize PLWCs within these communities for vaccination.

---

**FIG 1.** 3Cs vaccine hesitancy model and the possible roles CCSOs can play in improving vaccine acceptability. CCSO, cancer civil society organization; PLWC, people living with cancer.
How Can CCSOs Play A Role in Covid-19 Vaccination Programs?

Some of the strategies in which CCSOs can play an active role in COVID-19 vaccination programs include the following.

**CCSOs Being Used as Vaccination Centers for PLWCs.** CCSOs providing clinical services would already have suitable infrastructure and resources for registering, administering, and subsequently risk-assessing and observing PLWCs for unintended postvaccination events. CCSOs can be contracted by specific governments or international organizations to act as vaccination centers specifically for PLWCs and will also confer additional benefits by acting to decrease the load on clinical systems already managing active COVID-19 infections as well as being low-risk centers, which are a safer avenue for PLWCs at risk for COVID-19 infections. In specific instances, CCSOs can also establish and carry out mobile vaccination camps to reach vulnerable PLWCs or those in geographically inaccessible regions. Integrating the care of communicable and non-communicable diseases (NCDs) has been successfully carried out in Malawi, for example, where integrated HIV and NCD care was provided.26

**CCSOs Acting to Support Governments in Purchasing and Distributing COVID-19 Vaccines for PLWCs.** In LMICs with fragile overburdened health systems, CCSOs may be able to support governments in purchase and distribution of COVID-19 vaccines, specifically for PLWCs. This could be done working together with larger global partners and prove to be a manner in which vaccines can be provided to PLWCs, who are a high-priority group to be vaccinated. In countries such as India and Tanzania, civil society organizations have played an important part in providing access to essential medicines, and also acted to exercise wider market influence by controlling competition and prices.27

**CCSOs Advocating for Equitable Vaccine Access for COVID-19 Vaccines for PLWCs.** In LMICs, CCSOs can act as advocates to governments and other key stakeholders to ensure that PLWCs are prioritized in terms of vaccine access. CCSOs are perfectly positioned for this role since most already are in strong social partnerships with key public health stakeholders within their national settings. Additionally, CCSOs can act as public oversight bodies to ensure that the rollout of vaccines is being carried out in a systematic, transparent manner. CCSOs have successfully advocated for governments and other stakeholders to provide equitable access to medicines in various other disease settings, including in HIV.28

**CCSOs Providing Vaccine-Specific Health Education and Health Promotion.** CCSOs can play an important part in building the confidence of PLWCs as well as their families and carers to COVID-19 vaccines. Most CCSOs already have strong scientific reputations and good working relationships with experts, as well as the implicit trust of their communities. CCSOs can act to bridge the gap between the evidence of COVID-19 vaccines and PLWCs who are grappling with these abstract scientific concepts via innovative and effective communication approaches. These may include simplifying vaccine and side-effect data using social media or even celebrities to increase vaccine confidence and utilizing of existing channels used for dissemination of cancer information to include vaccine health education and health promotion.

CCSOs that are already in many instances actively involved in debunking cancer misinformation and pseudoscience should also extend these capabilities to counterbalance vaccine myths and the narrative of antivaxxers. One successful example of CCSOs acting to drive vaccine-specific health education and health promotion was during the promotion of HPV vaccination in Europe.29 In specific communities, CCSOs can also work with community cultural or religious leaders to identify possible beliefs that may hinder vaccine uptake by vulnerable populations and work to address them.30

The success of COVID-19 vaccination programs is one of the key checkpoints for ending the pandemic and, through this, provide a clear path to put cancer care back on track.2 CCSOs can and should play a role in vaccination programs in their own communities, especially in LMICs with fragile health systems that are severely under strain fighting the COVID-19 pandemic.

**AFFILIATIONS**

1National Cancer Society of Malaysia, Kuala Lumpur, Malaysia
2Union for International Cancer Control (UICC) Young Leaders Programme 2019/2020, Geneva, Switzerland
3Department of Global Health, University of Washington, Seattle, WA
4Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt
5Fundacion Aladina, Madrid, Spain
6Women’s Health Program, Cameroon Baptist Convention Health Services, Cameroon
7European Network for Smoking and Tobacco Prevention
8Department of Radiation Biology, Radiotherapy and Radiodiagnosis, College of Medicine, University of Lagos, Nigeria
9Sebeccly Cancer Care, Lagos, Nigeria
10Oncopadi Digital Clinic, Lagos, Nigeria
11Instituto do Câncer do Estado de São Paulo, Sao Paulo, Brazil
12European Society for Medical Oncology (ESMO), Lugano, Switzerland

**CORRESPONDING AUTHOR**

Muralitharan Munisamy, MD, MCommHSc, MSc, MMedEd, PhD, National Cancer Society Malaysia, 66 Jalan Raja Muda Abd Aziz, Kuala Lumpur 50300, Malaysia; e-mail: muralli@cancer.org.my.

**AUTHOR CONTRIBUTIONS**

Conception and design: Muralitharan Munisamy, Isthar Espejo, Alexandra Tamas, Felipe Roitberg
Administrative support: Murallitharan Munisamy  
Provision of study material or patients: Murallitharan Munisamy, Ahmed Abdelbadee, Isthar Espejo, Florence Manjuh, Alexandra Tamas, Omolola Salako  
Collection and assembly of data: Murallitharan Munisamy, Kingsley Ndoh, Ahmed Abdelbadee, Alexandra Tamas, Omolola Salako  
Data analysis and interpretation: Murallitharan Munisamy, Kingsley Ndoh, Isthar Espejo, Florence Manjuh, Felipe Roitberg  
Manuscript writing: All authors  
Final approval of manuscript: All authors  
Accountable for all aspects of the work: All authors  

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST  
The following represents disclosure information provided by the authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rec or ascopubs.org/go/authors/author-center.  
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).  

Muralitharan Munisamy  
Stock and Other Ownership Interests: Sanofi/Aventis, MMPKV  

HEALTHCARE SDN BHD  

REFERENCES  
1. World Health Organisation (WHO): Weekly Operational Updates on COVID-19 17 May 2021. Issue No: 55. 2021. https://www.who.int/publications/m/item/weekly-operational-update-covid-19—17-may-2021  
2. Skek D, Gluckman P, Boulton G, et al: Future scenarios for the COVID-19 pandemic. Lancet 397:777-778, 2021  
3. Forni G, Mantovani A: COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ 28:626-639, 2021  
4. Palliel AD, Schwartz JL, Zheng A, et al: Clinical outcomes of a COVID-19 vaccine: Implementation over efficacy. Study examines how definitions and thresholds of vaccine efficacy, coupled with different levels of implementation effectiveness and background epidemic severity, translate into outcomes. Health Aff (Millwood) 40:42-52, 2021  
5. Giannakoulis VG, Papoutsi E, Siempos II: Effect of cancer on clinical outcomes of patients with COVID-19: A meta-analysis of patient data. JCO Glob Oncol 6:799-808, 2020  
6. Riera R, Bagattini AM, Pacheco RL, et al: Delays and disruptions in cancer health care due to COVID-19 pandemic: Systematic review. JCO Glob Oncol 7:311-323, 2021  
7. European Cancer Organisation: Covid 19 & Cancer Data Intelligence. 2021. https://www.europeancancer.org/timetoact/impact/data-intelligence  
8. Nelson R: Organisations for patients with cancer feel the brunt of COVID-19 pandemic. Lancet Oncol 21:1020, 2020  
9. World Ovarian Cancer Coalition, World Pancreatic Cancer Coalition, Lymphoma Coalition, World Bladder Cancer Patient Coalition, ABC Global Alliance. The Impact of COVID-19 on Cancer Patient Organisations [Internet]. 2020. https://ikcc.org/wp-content/uploads/2020/08/The-impact-of-COVID-19-on-Cancer-Patient-Organisations-22nd-June-2020.pdf  
10. Pacheco RL, Martinimbio AN, Roitberg F, et al: Impact of strategies for mitigating delays and disruptions in cancer care due to COVID-19: Systematic review. JCO Glob Oncol 7:342-352, 2021  
11. Habry D: How COVID-19 vaccines could help put cancer care back on track, in Union for International Cancer Control (UICC) Blog, Geneva, Switzerland: UICC, 2021. https://www.uicc.org/blog/how-covid-19-vaccines-could-help-put-cancer-care-back-track  
12. MacDonald NE: Vaccine hesitancy: Definition, scope and determinants. Vaccine 33:4161-4164, 2015  
13. The SAGE Vaccine Hesitancy Working Group: Report of the SAGE Working Group on Vaccine Hesitancy. 2014. https://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKINGGROUP_vaccinehesitancy_final.pdf  
14. Sallam M: COVID-19 vaccine hesitancy worldwide: A concise systematic review of vaccine acceptance rates. Vaccines 9:160, 2021  
15. Fisher KA, Bloomstone SJ, Walder J, et al: Attitudes toward a potential SARS-CoV-2 vaccine: A survey of US adults. Ann Intern Med 173:964-973, 2020  
16. Repajic M, Lai XL, Xu P, Liu A: Bell’s Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy. Brain Behav Immun Health 13:10217, 2021  
17. Johns Hopkins University: COVID-19 Dashboard 2021 [May, 2021]. https://coronavirus.jhu.edu/map.html  
18. Chou WY, Budenz A: Considering emotion in COVID-19 vaccine communication: Addressing vaccine hesitancy and fostering vaccine confidence. Health Commun 35:1718-1722, 2020  
19. Shapiro CL: Cancer survivorship. N Engl J Med 379:2438-2450, 2018  
20. Desai A, Gainor JF, Hegde A: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol 18:313-319, 2021  
21. The New York Times Editorial, in The Vaccine Scramble, Cancer Patients Are Left Behind. New York Times, New York City 2021
22. Dooling K, McClung N, et al: The Advisory Committee on Immunization Practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine—United States, 2020. MMWR Morb Mortal Wkly Rep 69:1857-1859, 2020
23. Bollyky TJ, Gostin LO, Hamburg MA: The equitable distribution of COVID-19 therapeutics and vaccines. JAMA 323:2462-2463, 2020
24. Green MS, Abdullah R, Vered S, et al: A study of ethnic, gender and educational differences in attitudes toward COVID-19 vaccines in Israel—Implications for vaccination implementation policies. Isr J Health Pol Res 10:1-2, 2021
25. Bishwajit G, Iide S, Ghosh S: Social determinants of infectious diseases in South Asia. Int Sch Res Notices 2014:135243, 2014
26. Pfaff C, Scott V, Hoffman R, et al: You can treat my HIV—but can you treat my blood pressure? Availability of integrated HIV and non-communicable disease care in northern Malawi. Afr J Prim Health Care Fam Med 9:1-8, 2017
27. Mackintosh M, Chaudhuri S, Mujinja PG: Can NGOs regulate medicines markets? Social enterprise in wholesaling, and access to essential medicines. Global Health 7:1-3, 2011
28. Greer SL, Wismar M, Pastorino G, et al (eds): Civil Society and Health: Contributions and Potential. World Health Organization; Geneva, Switzerland 2017
29. Laurent-Ledru V, Thomson A, Monsonego J: Civil society: A critical new advocate for vaccination in Europe. Vaccine 29:624-628, 2011
30. Olagoke AA, Olagoke OO, Hughes AM: Intention to vaccinate against the novel 2019 coronavirus disease: The role of health locus of control and religiosity. J Religion Health 60:65-80, 2021